(Q46426075)

English

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.

scientific article published on 23 June 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. (English)

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

phase III clinical trial

0 references

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

author name string

Jatinder K Lamba

1

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

Lata Chauhan

2

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

Miyoung Shin

3

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

Michael R Loken

4

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

Jessica A Pollard

5

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

Yi-Cheng Wang

6

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

Rhonda E Ries

7

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

Richard Aplenc

8

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

Betsy A Hirsch

9

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

Susana C Raimondi

10

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

Roland B Walter

11

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

Irwin D Bernstein

12

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

Alan S Gamis

13

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

Todd A Alonzo

14

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

Soheil Meshinchi

15

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

language of work or name

0 references

publication date

23 June 2017

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

Journal of Clinical Oncology

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

35

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

23

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

2674-2682

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

Gemtuzumab ozogamicin in acute myeloid leukemia revisited

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

CD33 Alzheimer's risk-altering polymorphism, CD33 expression, and exon 2 splicing.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

Gemtuzumab ozogamicin: time to resurrect?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

Flow cytometric mean fluorescence intensity: the biophysics behind the number

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5549451

29 September 2018

AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/28644774

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemtuzumab ozogamicin: is there room for salvage?

1 reference

https://pubmed.ncbi.nlm.nih.gov/28644774

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/28644774

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2016.71.2513

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

0 references

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/28644774

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46426075&oldid=1521268670"